ANZCHOG coordinates some of the most important childhood cancer research across Australia and New Zealand
Our clinical trials registry brings together every active and upcoming trial in one place – giving families, clinicians, and researchers a clear picture of what’s available, where, and for whom.
Whether you’re exploring options for a child in your care or looking for a study site, this registry is your starting point.
An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies with repeated administration in patients with clinical benefit
, Brain and Spinal (Central Nervous System) Tumours, Digestive System Tumours, Endocrine Tumours, Eye Tumours, Female genital tumours, Genetic tumour syndromes, Germ Cell Tumours, Leukaemia / Lymphoma / Blood Disorders, Head and neck tumours, Neuroblastoma and Ganglioneuroblastoma, Kidney (Renal) Tumours, Skin tumours, Soft Tissue and Bone Tumours (Sarcoma), Chest and Lung (Thoracic) Tumours
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement
International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic
A Phase 3 Trial Investigating Blinatumomab (IND# 117467& NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients
Leukaemia / Lymphoma / Blood Disorders
1 year
|
31 years
Queensland Children’s Hospital
John Hunter Children’s Hospital
Perth Children’s Hospital
Children’s Hospital at Westmead
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
Leukaemia / Lymphoma / Blood Disorders
<21 years
Queensland Children’s Hospital
John Hunter Children’s Hospital
A Phase 2 Study of Veliparib (ABT-888, IND# 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E Mutations
A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed paediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
Brain and Spinal (Central Nervous System) Tumours
12 months
|
21 years
Queensland Children’s Hospital
Sydney Children’s Hospital
Royal Children’s Hospital
Perth Children’s Hospital
Children’s Hospital at Westmead
Starship Children’s Hospital
Christchurch Hospital
A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
Brain and Spinal (Central Nervous System) Tumours
3 years
|
29 years
Queensland Children’s Hospital
Sydney Children’s Hospital
Royal Children’s Hospital
Perth Children’s Hospital
Children’s Hospital at Westmead
Starship Children’s Hospital
Christchurch Hospital
, Brain and Spinal (Central Nervous System) Tumours, Digestive System Tumours, Endocrine Tumours, Eye Tumours, Female genital tumours, Genetic tumour syndromes, Germ Cell Tumours, Leukaemia / Lymphoma / Blood Disorders, Head and neck tumours, Neuroblastoma and Ganglioneuroblastoma, Kidney (Renal) Tumours, Skin tumours, Soft Tissue and Bone Tumours (Sarcoma), Chest and Lung (Thoracic) Tumours
<35 years
John Hunter Children’s Hospital
Monash Health Clayton
Royal Children’s Hospital
Women’s and Children’s Hospital
Perth Children’s Hospital
Children’s Hospital at Westmead
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk paediatric and Adult Patients with Germ Cell Tumors
Germ Cell Tumours
Various depending on risk group & consult protocol
Queensland Children’s Hospital
John Hunter Children’s Hospital
Sydney Children’s Hospital
Monash Health Clayton
Royal Children’s Hospital
Perth Children’s Hospital
Children’s Hospital at Westmead
Starship Children’s Hospital
Christchurch Hospital
International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia (A randomized Phase III study conducted by the AIEOP-BFM study group)
Application of innovative molecular profiling techniques to improve diagnosis of paediatric central nervous system tumours and develop an accredited Australasian molecular profiling service.
Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy
Leukaemia / Lymphoma / Blood Disorders
No limit
Royal Children’s Hospital
Children’s Hospital at Westmead
A Phase 1/2 Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults and Adolescents with Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) and Minimal Residual Disease Positive (MRD+) B-ALL
A phase 1b study to evaluate the safety, tolerability, pharmacokinetics and efficacy of xaluritamig in adult, adolescent and paediatric participants with relapsed or refractory Ewing sarcoma
A Phase 1B/2A Study of the Safety, Tolerability and Initial Efficacy of
Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine
(DFMO) in Patients with Cancer
A Phase 2 Randomised Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# TBD) in Children with Relapsed& Refractory or Progressive Neuroblastoma
Neuroblastoma and Ganglioneuroblastoma
>1 year
Queensland Children’s Hospital
Sydney Children’s Hospital
Royal Children’s Hospital
Women’s and Children’s Hospital
Perth Children’s Hospital
Children’s Hospital at Westmead
Pilot Study of Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination with Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic Germ Cell Tumours
A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
Soft Tissue and Bone Tumours (Sarcoma)
<40 years
Queensland Children’s Hospital
Sydney Children’s Hospital
Royal Children’s Hospital
Perth Children’s Hospital
Children’s Hospital at Westmead
Starship Children’s Hospital
Christchurch Hospital
Project: EveryChild A Registry and Eligibility Screening and Biology and Outcome Study
, Brain and Spinal (Central Nervous System) Tumours, Digestive System Tumours, Endocrine Tumours, Eye Tumours, Female genital tumours, Genetic tumour syndromes, Germ Cell Tumours, Leukaemia / Lymphoma / Blood Disorders, Head and neck tumours, Neuroblastoma and Ganglioneuroblastoma, Kidney (Renal) Tumours, Skin tumours, Soft Tissue and Bone Tumours (Sarcoma), Chest and Lung (Thoracic) Tumours
<25 years
Queensland Children’s Hospital
John Hunter Children’s Hospital
Sydney Children’s Hospital
Monash Health Clayton
Royal Children’s Hospital
Women’s and Children’s Hospital
Perth Children’s Hospital
Royal Hobart Hospital
Children’s Hospital at Westmead
Starship Children’s Hospital
Christchurch Hospital
NCI-COG paediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
, Brain and Spinal (Central Nervous System) Tumours, Digestive System Tumours, Endocrine Tumours, Eye Tumours, Female genital tumours, Genetic tumour syndromes, Germ Cell Tumours, Leukaemia / Lymphoma / Blood Disorders, Head and neck tumours, Neuroblastoma and Ganglioneuroblastoma, Kidney (Renal) Tumours, Skin tumours, Soft Tissue and Bone Tumours (Sarcoma), Chest and Lung (Thoracic) Tumours
NCI-COG paediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations
, Brain and Spinal (Central Nervous System) Tumours, Digestive System Tumours, Endocrine Tumours, Eye Tumours, Female genital tumours, Genetic tumour syndromes, Germ Cell Tumours, Leukaemia / Lymphoma / Blood Disorders, Head and neck tumours, Neuroblastoma and Ganglioneuroblastoma, Kidney (Renal) Tumours, Skin tumours, Soft Tissue and Bone Tumours (Sarcoma), Chest and Lung (Thoracic) Tumours
NCI-COG paediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations
, Brain and Spinal (Central Nervous System) Tumours, Digestive System Tumours, Endocrine Tumours, Eye Tumours, Female genital tumours, Genetic tumour syndromes, Germ Cell Tumours, Leukaemia / Lymphoma / Blood Disorders, Head and neck tumours, Neuroblastoma and Ganglioneuroblastoma, Kidney (Renal) Tumours, Skin tumours, Soft Tissue and Bone Tumours (Sarcoma), Chest and Lung (Thoracic) Tumours
A Multicenter, Open-label Phase 1b Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients with Unresectable or Metastatic BRAF V600-mutant Melanoma
A randomized Phase III study of vincristine& dactinomycin& cyclophosphamide (VAC) alternating with vincristine and irinotecan (VI) versus VAC/VI plus temsirolimus (TEM) in patients with intermediate risk (IR) rhabdomyosarcoma (RMS)
A Safety, Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor, Nirogacestat (PF-03084014) in Children and Adolescents With Progressive, Surgically Unresectable Desmoid Tumors
A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS)
Soft Tissue and Bone Tumours (Sarcoma)
<50 years
Queensland Children’s Hospital
Perth Children’s Hospital
Children’s Hospital at Westmead
A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) Versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Leukaemia / Lymphoma / Blood Disorders
6 months
|
21 years
Perth Children’s Hospital
Children’s Hospital at Westmead
Acute Lymphoblastic Leukaemia Subtype and Side-Effects from Treatment – Nationwide analysis of severe treatment-related toxicity in
childhood leukaemia
A randomised and open-label and active controlled and safety and extrapolated efficacy study in paediatric subjects requiring anticoagulation for the treatment of a venous thromboembolic event (Phase IV) Apixaban
A pilot study to test the feasibility and safety and efficacy of the addition of the BiTE antibody Blinatumomab to the Interfant-06 backbone in infants with MLL-rearranged acute lymphoblastic leukemia (A collaborative study of the Interfant network)
A Phase 1/2, Single-arm Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Avapritinib in paediatric Patients with Solid Tumors Dependent on KIT or PDGFRA Signaling
, Brain and Spinal (Central Nervous System) Tumours, Digestive System Tumours, Endocrine Tumours, Eye Tumours, Female genital tumours, Genetic tumour syndromes, Germ Cell Tumours, Leukaemia / Lymphoma / Blood Disorders, Head and neck tumours, Neuroblastoma and Ganglioneuroblastoma, Kidney (Renal) Tumours, Skin tumours, Soft Tissue and Bone Tumours (Sarcoma), Chest and Lung (Thoracic) Tumours
Implementing pharmacogenetics in the busulfan dosing method for children undergoing hematopoietic stem-cell transplantation: a prospective, multicentric, randomized clinical trial
Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Malignancies (PIVOT IO 020)
, Brain and Spinal (Central Nervous System) Tumours, Digestive System Tumours, Endocrine Tumours, Eye Tumours, Female genital tumours, Genetic tumour syndromes, Germ Cell Tumours, Leukaemia / Lymphoma / Blood Disorders, Head and neck tumours, Neuroblastoma and Ganglioneuroblastoma, Kidney (Renal) Tumours, Skin tumours, Soft Tissue and Bone Tumours (Sarcoma), Chest and Lung (Thoracic) Tumours
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in paediatric and Young Adult Participants with Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma
A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of asciminib in pediatric participants newly diagnosed or previously treated with Philadelphia positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) with or without known T315I mutation
A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with chemotherapy followed by asciminib plus blinatumomab in pediatric, adolescent, and young adult participants with relapsed or refractory BCR::ABL1-positive (Philadelphia positive, Ph+) or BCR::ABL1-like (Ph-like) acute lymphoblastic leukemia (ALL)
A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Irinotecan and Temozolomide in Participants With Relapsed or Refractory Ewing’s Sarcoma
A Phase 1 Study of CD19 Specific Chimeric Antigen Receptor T-cell for Therapy of persistent and Relapsed B-cell leukaemia and Lymphoma Post Allogeneic Stem Cell Transplantation (The CARTELL Study)
A Phase II single arm study to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in paediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS)
Genetic tumour syndromes
2 years
|
100 years
Sydney Children’s Hospital
Women’s and Children’s Hospital
A Two-stage Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib in paediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Soft Tissue and Bone Tumours (Sarcoma)
<100 years
Queensland Children’s Hospital
Sydney Children’s Hospital
Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG)
Phase 1b/2 Study of Carfilzomib in Combination with Dexamethasone and Mitoxantrone and PEG-asparaginase& and Vincristine (UK R3 Induction Backbone) in Children with Relapsed or Refractory Acute Lymphoblastic Leukaemia
A Phase I/II Open-label and Single-arm and Multi-center Study of Ruxolitinib Added to Corticosteroids in paediatric Patients With Grade II-IV Acute Graft vs. Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Cancer Information Registry for Children and Adolescents in Australia
, Brain and Spinal (Central Nervous System) Tumours, Digestive System Tumours, Endocrine Tumours, Eye Tumours, Female genital tumours, Genetic tumour syndromes, Germ Cell Tumours, Leukaemia / Lymphoma / Blood Disorders, Head and neck tumours, Neuroblastoma and Ganglioneuroblastoma, Kidney (Renal) Tumours, Skin tumours, Soft Tissue and Bone Tumours (Sarcoma), Chest and Lung (Thoracic) Tumours
No limit
John Hunter Children’s Hospital
Sydney Children’s Hospital
Monash Health Clayton
Royal Children’s Hospital
Women’s and Children’s Hospital
Perth Children’s Hospital
Royal Hobart Hospital
Children’s Hospital at Westmead
Phase I/II multicenter study to assess efficacy and safety of ribociclib (LEE011) in combination with topotecan and temozolomide (TOTEM) in paediatric patients with relapsed or refractory neuroblastoma and other solid tumors
Brain and Spinal (Central Nervous System) Tumours, Neuroblastoma and Ganglioneuroblastoma, Kidney (Renal) Tumours, Soft Tissue and Bone Tumours (Sarcoma)
A phase i/ii, open-label, single-arm, two-part trial to evaluate safety, tolerability, pharmacokinetics, and anti-tumor activity of glofitamab in combination with chemoimmunotherapy in paediatric and young adult participants with relapsed/refractory mature b-cell non-hodgkin lymphoma
Phase II Study of Ribociclib and Everolimus Following Radiotherapy in Pediatric and Young Adult Patients Newly Diagnosed with HighGrade Glioma (HGG), including Diffuse Intrinsic Pontine Glioma (DIPG), which Harbor Alterations of the Cell Cycle and/or PI3K/mTOR Pathways: A treatment arm within TarGeT
CNS tumours
12 months
|
39 years
Sydney Children’s Hospital
Royal Children’s Hospital
Perth Children’s Hospital
Phase 2 Study of Systemic IL-6 Receptor Antagonist ACTEMRA® (tocilizumab) for the treatment of Progressive/Recurrent paediatric Adamantinomatous Craniopharyngioma
Brain and Spinal (Central Nervous System) Tumours
1 year
|
39 years
Queensland Children’s Hospital
Sydney Children’s Hospital
Perth Children’s Hospital
A Phase 1, Open-label, Parallel Group Study to Investigate Olaparib Safety andTolerability, Efficacy and Pharmacokinetics in Paediatric Patients with Solid Tumours
, Brain and Spinal (Central Nervous System) Tumours, Digestive System Tumours, Endocrine Tumours, Eye Tumours, Female genital tumours, Genetic tumour syndromes, Germ Cell Tumours, Leukaemia / Lymphoma / Blood Disorders, Head and neck tumours, Neuroblastoma and Ganglioneuroblastoma, Kidney (Renal) Tumours, Skin tumours, Soft Tissue and Bone Tumours (Sarcoma), Chest and Lung (Thoracic) Tumours
<18 years
Queensland Children’s Hospital
Monash Health Clayton
Children’s Hospital at Westmead
A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in paediatric Patients With BRAF-Altered, Recurrent or Progressive Low-Grade Glioma
Brain and Spinal (Central Nervous System) Tumours
6 months
|
25 years
Queensland Children’s Hospital
Sydney Children’s Hospital
Perth Children’s Hospital
Children’s Hospital at Westmead
A Phase 1, Open-Label, Dose Escalation Study of CLR 131 in Children and Adolescents with Select Solid Tumors, Lymphoma, and Malignant Brain Tumors
Brain and Spinal (Central Nervous System) Tumours, Leukaemia / Lymphoma / Blood Disorders, Head and neck tumours, Neuroblastoma and Ganglioneuroblastoma, Soft Tissue and Bone Tumours (Sarcoma)
A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children, Adolescents and Young Adults with Relapsed or Refractory Osteosarcoma
A Phase 1 Study of Intravenous EGFR-ErbituxEDVSMIT (EEDVSMit) in Children with Recurrent / Refractory Solid or Brain and Spinal (Central Nervous System) Tumours Expressing Epidermal Growth Factor Receptor (EGFR)
, Brain and Spinal (Central Nervous System) Tumours, Digestive System Tumours, Endocrine Tumours, Eye Tumours, Female genital tumours, Genetic tumour syndromes, Germ Cell Tumours, Leukaemia / Lymphoma / Blood Disorders, Head and neck tumours, Neuroblastoma and Ganglioneuroblastoma, Kidney (Renal) Tumours, Skin tumours, Soft Tissue and Bone Tumours (Sarcoma), Chest and Lung (Thoracic) Tumours
A Phase 3 Open-label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated paediatric Patients <12 Years of Age With Severe Hemophilia A
European Network-Paediatric Hodgkin Lymphoma Study Group (EuroNet-PHL) Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents
A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients With paediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy
Brain and Spinal (Central Nervous System) Tumours
<25 years
Queensland Children’s Hospital
Sydney Children’s Hospital
Perth Children’s Hospital
Children’s Hospital at Westmead
Starship Children’s Hospital
A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF Class 1 and Class 2 alterations, in participants with cancer harboring BRAF alterations
, Brain and Spinal (Central Nervous System) Tumours, Digestive System Tumours, Endocrine Tumours, Eye Tumours, Female genital tumours, Genetic tumour syndromes, Germ Cell Tumours, Leukaemia / Lymphoma / Blood Disorders, Head and neck tumours, Neuroblastoma and Ganglioneuroblastoma, Kidney (Renal) Tumours, Skin tumours, Soft Tissue and Bone Tumours (Sarcoma), Chest and Lung (Thoracic) Tumours
Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation With Randomization to Either Single Cycle or to Three Tandem Cycles of Marrow-Ablative Chemotherapy With Autologous Hematopoietic Progenitor Cell Rescue
Brain and Spinal (Central Nervous System) Tumours
<10 years
Children’s Hospital at Westmead
Christchurch Hospital
A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in paediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors and Abemaciclib in Combination With Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in paediatric and Young Adult Patients With Relapsed/Refractory Neuroblastoma (Part C)
, Brain and Spinal (Central Nervous System) Tumours, Digestive System Tumours, Endocrine Tumours, Eye Tumours, Female genital tumours, Genetic tumour syndromes, Germ Cell Tumours, Leukaemia / Lymphoma / Blood Disorders, Head and neck tumours, Neuroblastoma and Ganglioneuroblastoma, Kidney (Renal) Tumours, Skin tumours, Soft Tissue and Bone Tumours (Sarcoma), Chest and Lung (Thoracic) Tumours
Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in
Combination With Temozolomide Compared to Temozolomide Monotherapy in Children and
Young Adults With Newly Diagnosed High-Grade Glioma Following Radiotherapy
Brain and Spinal (Central Nervous System) Tumours
<20 years
Queensland Children’s Hospital
Children’s Hospital at Westmead
A Phase I/II, Open-Label, Multicenter, Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in paediatric Patients With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available
, Brain and Spinal (Central Nervous System) Tumours, Digestive System Tumours, Endocrine Tumours, Eye Tumours, Female genital tumours, Genetic tumour syndromes, Germ Cell Tumours, Leukaemia / Lymphoma / Blood Disorders, Head and neck tumours, Neuroblastoma and Ganglioneuroblastoma, Kidney (Renal) Tumours, Skin tumours, Soft Tissue and Bone Tumours (Sarcoma), Chest and Lung (Thoracic) Tumours
<17 years
Queensland Children’s Hospital
Sydney Children’s Hospital
Royal Children’s Hospital
Perth Children’s Hospital
Children’s Hospital at Westmead
INFORM2 exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
, Brain and Spinal (Central Nervous System) Tumours, Digestive System Tumours, Endocrine Tumours, Eye Tumours, Female genital tumours, Genetic tumour syndromes, Germ Cell Tumours, Leukaemia / Lymphoma / Blood Disorders, Head and neck tumours, Neuroblastoma and Ganglioneuroblastoma, Kidney (Renal) Tumours, Skin tumours, Soft Tissue and Bone Tumours (Sarcoma), Chest and Lung (Thoracic) Tumours
A clinical trial of donor-derived WT1 specific T cells for prevention of relapse in combination with multiple pathogen specific T cells for prevention of infection in patients undergoing allogeneic haemopoietic stem cell transplant for acute myeloid leukaemia
International collaborative treatment protocol for infants under one year with KMT2Arearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia
Leukaemia / Lymphoma / Blood Disorders
1 day
|
1 year
John Hunter Children’s Hospital
Sydney Children’s Hospital
Monash Health Clayton
Women’s and Children’s Hospital
Perth Children’s Hospital
Children’s Hospital at Westmead
Starship Children’s Hospital
Christchurch Hospital
A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 erbumine as a Single Agent and in Combination in Patients with Relapsed/Refractory Neuroblastoma
CAMPFIRE: A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in paediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor
Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in paediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Synovial Sarcoma
A phase II & open-labeled & multi-center & randomized controlled trial of Vinblastine +/- Bevacizumab for the treatment of chemotherapy-naive children with unresectable or progressive low grade glioma
LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the
Safety and Efficacy of Zilovertamab Vedotin in paediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors
Leukaemia / Lymphoma / Blood Disorders, Neuroblastoma and Ganglioneuroblastoma, Soft Tissue and Bone Tumours (Sarcoma)
6 months
|
25 years
Queensland Children’s Hospital
Sydney Children’s Hospital
Royal Children’s Hospital
LIGHTBEAM-U01 Substudy 01C: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruta in paediatric Participants With Relapsed or Refractory Solid Tumors
, Brain and Spinal (Central Nervous System) Tumours, Digestive System Tumours, Endocrine Tumours, Eye Tumours, Female genital tumours, Genetic tumour syndromes, Germ Cell Tumours, Leukaemia / Lymphoma / Blood Disorders, Head and neck tumours, Neuroblastoma and Ganglioneuroblastoma, Kidney (Renal) Tumours, Skin tumours, Soft Tissue and Bone Tumours (Sarcoma), Chest and Lung (Thoracic) Tumours
1 months
|
17 years
Queensland Children’s Hospital
Sydney Children’s Hospital
Royal Children’s Hospital
A Phase 3 Open-label, Multicenter Study of the Long-term Safety and Efficacy of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Patients With Severe Hemophilia A
Leukaemia / Lymphoma / Blood Disorders, Neuroblastoma and Ganglioneuroblastoma, Soft Tissue and Bone Tumours (Sarcoma)
Phase III randomized double-blind placebo-controlled trial of metformin for cognitive recovery and white matter growth in paediatric patients with a brain tumour.
Brain and Spinal (Central Nervous System) Tumours
7 years
|
21 years
John Hunter Children’s Hospital
Monash Health Clayton
Royal Children’s Hospital
Women’s and Children’s Hospital
Perth Children’s Hospital
A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced and relapsed or refractory solid tumor or lymphoma
, Brain and Spinal (Central Nervous System) Tumours, Digestive System Tumours, Endocrine Tumours, Eye Tumours, Female genital tumours, Genetic tumour syndromes, Germ Cell Tumours, Leukaemia / Lymphoma / Blood Disorders, Head and neck tumours, Neuroblastoma and Ganglioneuroblastoma, Kidney (Renal) Tumours, Skin tumours, Soft Tissue and Bone Tumours (Sarcoma), Chest and Lung (Thoracic) Tumours
An Open-Label, Multicenter Phase 2 Basket Study to Evaluate the Antitumor Activity and Safety of Lenvatinib in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Malignancies
, Brain and Spinal (Central Nervous System) Tumours, Digestive System Tumours, Endocrine Tumours, Eye Tumours, Female genital tumours, Genetic tumour syndromes, Germ Cell Tumours, Leukaemia / Lymphoma / Blood Disorders, Head and neck tumours, Neuroblastoma and Ganglioneuroblastoma, Kidney (Renal) Tumours, Skin tumours, Soft Tissue and Bone Tumours (Sarcoma), Chest and Lung (Thoracic) Tumours
A Phase 2b open-label & single-arm study to evaluate pharmacokinetics& efficacy& safety and tolerability of letermovir in paediatric participants from birth to <18 years of age at risk of developing CMV infection and/or disease following allogeneic HSCT
International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia – Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination with Induction Chemotherapy
NANT 2012-01 Phase 1 study of Difluoromethylornithine (DFMO) and celecoxib with cyclophosphamide/topotecan for patients with relapsed or refractory neuroblastoma
Prospective Study Registry of Neuroblastoma and Ganglioneuroblastoma Presenting with Spinal Canal Involvement (SCI)
Neuroblastoma and Ganglioneuroblastoma
< 18 years
Queensland Children’s Hospital
John Hunter Children’s Hospital
Sydney Children’s Hospital
Monash Health Clayton
Women’s and Children’s Hospital
Perth Children’s Hospital
Royal Hobart Hospital
Children’s Hospital at Westmead
- Chris O'Brien Lifehouse - Peter MacCallum Cancer Centre - Princess Alexandra Hospital - Royal Adelaide Hospital
NORTH STUDY
A Phase II Study of Panobinostat in Paediatric& Adolescent and Young Adult Patients with Solid Tumours Including Osteosarcoma& Malignant Rhabdoid Tumour/Atypical Teratoid Rhabdoid Tumours and Neuroblastoma
Brain and Spinal (Central Nervous System) Tumours, Neuroblastoma and Ganglioneuroblastoma, Soft Tissue and Bone Tumours (Sarcoma)
ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
Brain and Spinal (Central Nervous System) Tumours
No limit
Queensland Children’s Hospital
Sydney Children’s Hospital
Perth Children’s Hospital
Royal Hobart Hospital
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer: A Phase I/II precision oncology basket trial of precision guided molecularly-targeted agents in children and adolescents with advanced brain and solid tumours
, Brain and Spinal (Central Nervous System) Tumours, Digestive System Tumours, Endocrine Tumours, Eye Tumours, Female genital tumours, Genetic tumour syndromes, Germ Cell Tumours, Leukaemia / Lymphoma / Blood Disorders, Head and neck tumours, Neuroblastoma and Ganglioneuroblastoma, Kidney (Renal) Tumours, Skin tumours, Soft Tissue and Bone Tumours (Sarcoma), Chest and Lung (Thoracic) Tumours
1 year
|
21 years
Queensland Children’s Hospital
John Hunter Children’s Hospital
Sydney Children’s Hospital
Monash Health Clayton
Royal Children’s Hospital
Women’s and Children’s Hospital
Perth Children’s Hospital
Royal Hobart Hospital
Children’s Hospital at Westmead
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer: A Phase I/II precision oncology basket trial of precision guided molecularly-targeted agents in children and adolescents with advanced brain and solid tumours
, Brain and Spinal (Central Nervous System) Tumours, Digestive System Tumours, Endocrine Tumours, Eye Tumours, Female genital tumours, Genetic tumour syndromes, Germ Cell Tumours, Leukaemia / Lymphoma / Blood Disorders, Head and neck tumours, Neuroblastoma and Ganglioneuroblastoma, Kidney (Renal) Tumours, Skin tumours, Soft Tissue and Bone Tumours (Sarcoma), Chest and Lung (Thoracic) Tumours
1 year
|
21 years
Queensland Children’s Hospital
John Hunter Children’s Hospital
Sydney Children’s Hospital
Monash Health Clayton
Perth Children’s Hospital
Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ALVR105 (Viralym-M) Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High-Risk Patients After Allogeneic Hematopoietic Cell Transplant.
Multicentre, investigator-initiated phase I/II clinical trial to assess safety and efficacy of personalised mRNA vaccine targeting tumour-associated neoantigens in children and young adults with high-risk brain tumours: the PaedNeoVax study
A Pharmacokinetic Study of Vincristine in Infants Dosed According to BSA Banded Infant Dosing Tables and Older Children Dosed by Traditional BSA Methods
, Brain and Spinal (Central Nervous System) Tumours, Digestive System Tumours, Endocrine Tumours, Eye Tumours, Female genital tumours, Genetic tumour syndromes, Germ Cell Tumours, Leukaemia / Lymphoma / Blood Disorders, Head and neck tumours, Neuroblastoma and Ganglioneuroblastoma, Kidney (Renal) Tumours, Skin tumours, Soft Tissue and Bone Tumours (Sarcoma), Chest and Lung (Thoracic) Tumours
A Single Arm, Pilot of Neoadjuvant Checkpoint Inhibition followed by Adjuvant Checkpoint Inhibition in Children and Young Adults with Recurrent or Progressive High Grade Glioma (HGG)
A combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGS) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression
A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in paediatric Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation
Assessment of the Utility of Family-based (Trio) Whole-genome Sequencing for Cancer Predisposition Testing in Sequential Newly Diagnosed Paediatric and Adolescent Cancer Patients
Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)
A Phase 1/2 Open-Label, Safety and Efficacy Study of Neoadjuvant Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) and Cemiplimab Alone Followed by Adjuvant Fianlimab in Combination With Cemiplimab in Pediatric and Young Adult Participants With Recurrent or Progressive High-Grade Glioma or Pediatric and Adult Participants With Recurrent or Progressive Posterior Fossa-A Ependymoma
A phase 1 trial of HLA-DR matched third party donor-derived fungus-specific cytotoxic T-lymphocytes in patients with invasive fungal disease post-allogeneic stem cell transplantation
Leukaemia / Lymphoma / Blood Disorders
1 year
|
80 years
Perth Children’s Hospital
Children’s Hospital at Westmead
A Phase III Randomized Open-Label Multi-centre Study of Ruxolitinib versus best available therapy in patients with Corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantation
Phase Ib study of the combination of regorafenib with conventional chemotherapy for the treatment of newly diagnosed patients with multimetastatic Ewing Sarcoma
A Phase II Canadian paediatric Brain Tumour Consortium Study of Re-Irradiation as Treatment of Progressive or Recurrent Diffuse Intrinsic Pontine Glioma
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
A Phase 2, single arm, open-label study of vorasidenib in pediatric participants aged 12 to < 18 years old with Grade 2 astrocytoma or oligodendroglioma with an IDH1 or IDH2 mutation
Phase 1 Evaluation Of Ly2606368& A Molecularly Targeted Chk1/2 Inhibitor Therapy& In Combination With Cyclophosphamide Or Gemcitabine For Children And Adolescents With Refractory Or Recurrent Group 3/Group 4 Or Shh Medulloblastoma Brain Tumors
A retrospective cohort study of response and survival in paediatric patients with relapsed and refractory acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LLy) treated with contemporary salvage therapy
Leukaemia / Lymphoma / Blood Disorders
<21 years
Royal Children’s Hospital
Children’s Hospital at Westmead
A Phase I Study of Tagraxofusp With or Without Chemotherapy in paediatric Patients with Relapsed or Refractory CD123 Expressing Hematologic Malignancies
A Phase 3, Open-label, Single-arm, Repeated-dose Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)
Leukaemia / Lymphoma / Blood Disorders
<17 years
Queensland Children’s Hospital
Sydney Children’s Hospital
Royal Children’s Hospital
Perth Children’s Hospital
Phase II Study of Ribociclib and Everolimus Following Radiotherapy in paediatric and Young Adult Patients Newly Diagnosed with HighGrade Glioma (HGG), including Diffuse Intrinsic Pontine Glioma (DIPG), which Harbor Alterations of the Cell Cycle and/or PI3K/mTOR Pathways: A treatment arm within TarGeT
Brain and Spinal (Central Nervous System) Tumours
12 months
|
39 years
Sydney Children’s Hospital
Royal Children’s Hospital
Perth Children’s Hospital
Phase 2 Study of Olutasidenib with Temozolomide as Maintenance Therapy in paediatric and Young Adult Patients Newly Diagnosed with High-Grade Glioma (HGG), including Diffuse Intrinsic Pontine Glioma (DIPG), which Harbor IDH1 Mutations
Brain and Spinal (Central Nervous System) Tumours
12 years
|
39 years
Sydney Children’s Hospital
Perth Children’s Hospital
Molecularly-Guided Phase II Umbrella Trial for Children, Adolescents, and Young Adults Newly Diagnosed with High-Grade Glioma (HGG), including Diffuse Intrinsic Pontine Glioma (DIPG) – SCREENING PROTOCOL
Brain and Spinal (Central Nervous System) Tumours
12 months
|
39 years
Queensland Children’s Hospital
Sydney Children’s Hospital
Royal Children’s Hospital
Perth Children’s Hospital
Preventing adverse events during paediatric cancer treatment: A multi-site hybrid randomised controlled trial of catheter lock solutions (The CLOCK trial)
, Brain and Spinal (Central Nervous System) Tumours, Digestive System Tumours, Endocrine Tumours, Eye Tumours, Female genital tumours, Genetic tumour syndromes, Germ Cell Tumours, Leukaemia / Lymphoma / Blood Disorders, Head and neck tumours, Neuroblastoma and Ganglioneuroblastoma, Kidney (Renal) Tumours, Skin tumours, Soft Tissue and Bone Tumours (Sarcoma), Chest and Lung (Thoracic) Tumours
<18 years
Queensland Children’s Hospital
Monash Health Clayton
Royal Children’s Hospital
Starship Children’s Hospital
A phase II study of trametinib in paediatric, adolescent and young adult patients with neurofibromatosis type 1 associated plexiform neurofibromas or progressive optic pathway gliomas
Brain and Spinal (Central Nervous System) Tumours, Genetic tumour syndromes, Neuroblastoma and Ganglioneuroblastoma
A phase 1/2, open-label safety, tolerability, pharmacokinetics and anti-tumour activity study of repotrectinib in paediatric and young adult subjects with advanced or metastatic malignancies harbouring ALK, ROS1 or NTRK1-3 alterations
, Brain and Spinal (Central Nervous System) Tumours, Digestive System Tumours, Endocrine Tumours, Eye Tumours, Female genital tumours, Genetic tumour syndromes, Germ Cell Tumours, Leukaemia / Lymphoma / Blood Disorders, Head and neck tumours, Neuroblastoma and Ganglioneuroblastoma, Kidney (Renal) Tumours, Skin tumours, Soft Tissue and Bone Tumours (Sarcoma), Chest and Lung (Thoracic) Tumours
<25 years
Queensland Children’s Hospital
Sydney Children’s Hospital
Perth Children’s Hospital
Children’s Hospital at Westmead
A Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patients with Replication-Repair Deficient (RRD) High-Grade Gliomas (HGG)
A Pilot Study to Investigate Safety and Efficacy of Weekly Combination of Intravenous Vinblastine with Oral Type II RAF Inhibitor Tovorafenib in paediatric Patient with Recurrent/ Progressive RAF Altered (non-NF1) Low Grade Gliomas
Brain and Spinal (Central Nervous System) Tumours
≤ 25 years
Queensland Children’s Hospital
John Hunter Children’s Hospital
Monash Health Clayton
Royal Children’s Hospital
Women’s and Children’s Hospital
Perth Children’s Hospital
Royal Hobart Hospital
Brain and Spinal (Central Nervous System) Tumours, Digestive System Tumours, Endocrine Tumours, Eye Tumours, Female genital tumours, Genetic tumour syndromes, Germ Cell Tumours, Leukaemia / Lymphoma / Blood Disorders, Head and neck tumours, Neuroblastoma and Ganglioneuroblastoma, Kidney (Renal) Tumours, Skin tumours, Soft Tissue and Bone Tumours (Sarcoma), Chest and Lung (Thoracic) Tumours
< 25 years
Queensland Children’s Hospital
John Hunter Children’s Hospital
Sydney Children’s Hospital
Monash Health Clayton
Royal Children’s Hospital
Women’s and Children’s Hospital
Perth Children’s Hospital
Royal Hobart Hospital
Children’s Hospital at Westmead
Starship Children’s Hospital
Christchurch Hospital
